Meeting
2014 ASCO Annual Meeting
Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
Authors
Laszlo Urban
Matrahaza Healthcare Center and University Teaching Hospital, Matrahaza, Hungary
Laszlo Urban , Allen Poma , Michelle Motta Dardeno , Robert E. Martell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01500226
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9636)
DOI
10.1200/jco.2014.32.15_suppl.9636
Abstract #
9636
Poster Bd #
286
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC).
First Author: Ian D. Schnadig
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers.
First Author: Rudolph M. Navari
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.
First Author: Rudolph M. Navari
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non–anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
First Author: Daniel Powers